The vaccine crisis at Astra Zeneca creates opportunities in a market where demand is much higher than supply anyway. In this context, Pfizer executives informed investors about the “significant opportunity” to increase the prices of the Pfizer-BioNTech vaccine, Business Insider announces.
Speaking at the Barclays Global Healthcare virtual conference, two company officials – Frank D’Amelio, CFO and Chuck Triano, senior vice president for investor relations – said Pfizer will have a chance to raise vaccine prices when COVID passes from a pandemic to an endemic situation.
D’Amelio says that with the resumption of “normal market conditions” over time, there would be a chance for the company to take advantage of opportunities from a “demand … and price perspective”.
The two added that in order to remain protected, people may need a third dose of vaccine to boost immunity and effectiveness against emerging variants of COVID.
In addition to the regular annual recalls, this vaccination cycle can become part of the new normal.
“We believe it is becoming increasingly likely that an annual vaccination will take place,” D’Amelio said, noting that Pfizer did not see the resulting pandemic or vaccination as a single event.
The Astra Zeneca crisis could be unblocked this week, when the report of the World Health Organization and the European Medicines Agency will be announced. If the two institutions certify that there are problems with this type of vaccine, then the whole market will be blown up, and Pfizer seems ready to cover the gap.
Meanwhile, 11 countries in Europe have suspended vaccination with Astra Zeneca, but also in Romania or other countries where it continues, the rate of rejection by the population has increased exponentially.
Basically, the countries in Europe will be put between a hammer and anvil: either they pay more for Pfizer or they risk Astra Zeneca, these being the companies that have a production that ensures the needs of the market at a decent level.
– .
